Short Interest in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Expands By 13.6%

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 595,300 shares, a growth of 13.6% from the December 15th total of 523,900 shares. Approximately 7.5% of the shares of the company are sold short. Based on an average trading volume of 260,300 shares, the days-to-cover ratio is presently 2.3 days.

Citius Pharmaceuticals Stock Performance

NASDAQ:CTXR opened at $3.30 on Monday. Citius Pharmaceuticals has a 52 week low of $2.44 and a 52 week high of $26.75. The firm’s 50-day simple moving average is $4.09 and its 200 day simple moving average is $10.92. The firm has a market cap of $25.51 million, a price-to-earnings ratio of -0.55 and a beta of 1.30.

Wall Street Analyst Weigh In

CTXR has been the topic of several research analyst reports. D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Citius Pharmaceuticals in a research report on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Citius Pharmaceuticals in a research note on Tuesday, November 12th.

Institutional Trading of Citius Pharmaceuticals

A number of institutional investors have recently modified their holdings of CTXR. Armistice Capital LLC bought a new stake in Citius Pharmaceuticals during the second quarter worth about $5,928,000. Cubist Systematic Strategies LLC bought a new stake in shares of Citius Pharmaceuticals during the 2nd quarter worth approximately $69,000. Point72 DIFC Ltd acquired a new stake in shares of Citius Pharmaceuticals during the 2nd quarter worth approximately $29,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Citius Pharmaceuticals in the second quarter valued at approximately $118,000. Finally, Wealth Advisory Solutions LLC raised its position in Citius Pharmaceuticals by 33.1% during the third quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company’s stock valued at $101,000 after purchasing an additional 50,000 shares in the last quarter. 16.88% of the stock is currently owned by institutional investors.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.